Eric Gauthier

4.9k total citations · 4 hit papers
42 papers, 3.1k citations indexed

About

Eric Gauthier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Eric Gauthier has authored 42 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Eric Gauthier's work include Advanced Breast Cancer Therapies (31 papers), Cancer-related Molecular Pathways (11 papers) and HER2/EGFR in Cancer Research (8 papers). Eric Gauthier is often cited by papers focused on Advanced Breast Cancer Therapies (31 papers), Cancer-related Molecular Pathways (11 papers) and HER2/EGFR in Cancer Research (8 papers). Eric Gauthier collaborates with scholars based in United States, France and Germany. Eric Gauthier's co-authors include Dongrui R. Lu, Hope S. Rugo, Richard S. Finn, Karen A. Gelmon, Véronique Dièras, Dennis J. Slamon, Nadia Harbeck, Oleg Lipatov, Miguel Martín and Janice M. Walshe and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Eric Gauthier

37 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Palbociclib and Letrozole in Advanced Breast Cancer

2016 1.9k citations Richard S. Finn, Miguel Martín et al. profile →
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

2019 286 citations Hope S. Rugo, Richard S. Finn et al. Breast Cancer Research and Treatment profile →
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

2022 109 citations Richard S. Finn, Hope S. Rugo et al. Journal of Clinical Oncology profile →
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

2024 81 citations Dennis J. Slamon, Véronique Dièras et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Gauthier United States	17	2.6k	2.4k	928	650	357	42	3.1k
Martin Frenzel United States	14	3.7k 1.4×	3.2k 1.3×	1.3k 1.4×	998 1.5×	402 1.1×	28	4.1k
Meritxell Bellet Spain	19	988 0.4×	1.4k 0.6×	618 0.7×	253 0.4×	656 1.8×	70	2.1k
S. Phan United States	15	1.4k 0.5×	1.6k 0.7×	525 0.6×	547 0.8×	495 1.4×	43	2.5k
Kathy Puyana Theall United States	9	2.1k 0.8×	1.9k 0.8×	814 0.9×	550 0.8×	286 0.8×	26	2.4k
Scott Cruickshank United States	21	1.0k 0.4×	1.2k 0.5×	368 0.4×	582 0.9×	741 2.1×	56	2.6k
Eva Ciruelos Spain	15	1.4k 0.5×	1.5k 0.6×	936 1.0×	399 0.6×	924 2.6×	76	2.5k
Giancarlo Bisagni Italy	25	832 0.3×	1.9k 0.8×	747 0.8×	267 0.4×	570 1.6×	127	2.9k
Ravindranath Patel United States	7	1.5k 0.6×	1.4k 0.6×	596 0.6×	365 0.6×	272 0.8×	15	1.8k
Edda Simoncini Italy	26	753 0.3×	1.7k 0.7×	1.1k 1.1×	170 0.3×	440 1.2×	99	2.5k
Rashmi K. Murthy United States	24	974 0.4×	2.3k 0.9×	599 0.6×	240 0.4×	644 1.8×	85	2.9k

Countries citing papers authored by Eric Gauthier

Since Specialization

Citations

This map shows the geographic impact of Eric Gauthier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Gauthier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Gauthier more than expected).

Fields of papers citing papers by Eric Gauthier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Gauthier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Gauthier. The network helps show where Eric Gauthier may publish in the future.

Co-authorship network of co-authors of Eric Gauthier

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Gauthier. A scholar is included among the top collaborators of Eric Gauthier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Gauthier. Eric Gauthier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harbeck, Nadia, Véronique Dièras, Karen A. Gelmon, et al.. (2025). Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial. ESMO Open. 10(4). 104497–104497.

Rocque, Gabrielle B., Joanne L. Blum, Yan Ji, et al.. (2024). Abstract PO3-05-11: Enhancing the interpretation of real-world quality of life (QoL) in patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+/HER2−) advanced breast cancer (ABC) enrolled in the POLARIS trial. Cancer Research. 84(9_Supplement). PO3–5.

Rimawi, Mothaffar F., Stephen Johnston, Samuel A. Jacobs, et al.. (2024). Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. npj Breast Cancer. 10(1). 54–54.

Tripathy, Debu, Joanne L. Blum, Meghan Karuturi, et al.. (2024). Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial. The Oncologist. 30(7). 2 indexed citations

Slamon, Dennis J., Véronique Dièras, Hope S. Rugo, et al.. (2024). Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Journal of Clinical Oncology. 42(9). 994–1000. 81 indexed citations breakdown →

Oikonomidou, Olga, Achim Wöckel, Rohan Parikh, et al.. (2023). 213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe. ESMO Open. 8(1). 101402–101402.

Blum, Joanne L., Gabrielle B. Rocque, Yan Ji, et al.. (2023). 461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial. Annals of Oncology. 34. S375–S375. 2 indexed citations

Finn, Richard S., Hope S. Rugo, Karen A. Gelmon, et al.. (2021). Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. The Oncologist. 26(5). e749–e755. 40 indexed citations

Finn, Richard S., Massimo Cristofanilli, Johannes Ettl, et al.. (2020). Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment. 184(1). 23–35. 25 indexed citations

10.

Rugo, Hope S., Richard S. Finn, Véronique Dièras, et al.. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment. 174(3). 719–729. 286 indexed citations breakdown →

11.

Dièras, Véronique, Nadia Harbeck, Anil A. Joy, et al.. (2019). Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. The Oncologist. 24(12). 1514–1525. 55 indexed citations

12.

Dièras, Véronique, Hope S. Rugo, Patrick Schnell, et al.. (2018). Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. JNCI Journal of the National Cancer Institute. 111(4). 419–430. 67 indexed citations

13.

Durairaj, Chandrasekar, Ana Ruiz-Garcı́a, Eric Gauthier, et al.. (2018). Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs. 29(3). 271–280. 33 indexed citations

14.

Dièras, Véronique, Nadia Harbeck, Anil A. Joy, et al.. (2017). PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L). Annals of Oncology. 28. v96–v96. 6 indexed citations

15.

Finn, Richard S., Karen A. Gelmon, Johannes Ettl, et al.. (2017). Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis. Annals of Oncology. 28. v79–v80. 2 indexed citations

16.

Im, S.-A., Hirofumi Mukai, Norikazu Masuda, et al.. (2016). 116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Annals of Oncology. 27. ix35–ix35. 5 indexed citations

17.

Gaudelus, J., et al.. (2016). La simplification du calendrier vaccinal est-elle appliquée ? Bilan 2ans après sa mise en place. Archives de Pédiatrie. 23(10). 1012–1017. 4 indexed citations

18.

Brummel‐Ziedins, Kathleen E., Phillip H. Lam, Matthew Gissel, Eric Gauthier, & David J. Schneider. (2013). Depletion of systemic concentrations of coagulation factors in blood from patients with atherosclerotic vascular disease. Coronary Artery Disease. 24(6). 468–474. 7 indexed citations

19.

Ray‐Coquard, Isabelle, Antoîne Italiano, Emmanuelle Bompas, et al.. (2012). Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). The Oncologist. 17(2). 260–266. 148 indexed citations

20.

Wenisch, É., et al.. (2005). Méthode de prise en charge globale non médicamenteuse des patients déments institutionnalisés. Revue Neurologique. 161(3). 290–298. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact